Study S000446

A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg With Placebo on Glycemic Control in Patients With Type 2 Diabetes on Basal Insulin Glargine

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02152371
Acronym: AWARD-9
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 300
Start: 2014-05
Primary completion: 2015-10
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Dulaglutide; DRUG:Placebo; DRUG:Insulin Glargine; DRUG:Metformin
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:H9X-MC-GBDI; EUDRACT_NUMBER:2012-004229-25

Registered primary outcomes

Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c) [Baseline, 28 Weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0024573	Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration. Pantalone KM, Diabetes, obesity & metabolism	2018	Randomized trial	PMID 29430801 DOI	cites ClinicalTrials.gov:NCT02152371; registry reference DERIVED:29430801
R0024710	Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9). Yu M, Clinical therapeutics	2017	Randomized trial	PMID 29110972 DOI	cites ClinicalTrials.gov:NCT02152371; registry reference DERIVED:29110972